Trials / Completed
CompletedNCT00289029
A Study of Two Iodinated Contrast Agents in Renally Impaired Patients Undergoing Cardiac Angiography
Visipaque and Isovue in Cardiac Angiography in Renally Impaired Patients
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 400 (planned)
- Sponsor
- Bracco Diagnostics, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to compare the incidence of contrast induced nephrotoxicity following the administration of Isovue or Visipaque in patients with moderate to severe renal insufficiency undergoing cardiac angiography. Serum creatinine will be measured before and up to 48-72 hours after the administration of the contrast agent to evaluate renal function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Iopamidol 370 mgI/mL |
Timeline
- Start date
- 2005-07-01
- Completion
- 2006-06-01
- First posted
- 2006-02-09
- Last updated
- 2006-08-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00289029. Inclusion in this directory is not an endorsement.